NCT02047500 2025-05-11
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
ImmunoGenesis
Phase 1 Terminated
Clinical Trials
7 trialsNCT01833546 2018-10-15
A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03098160 2017-10-30
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
Threshold Pharmaceuticals
Phase 1 Unknown
NCT02020226 2016-06-02
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Unknown
NCT01149915 2015-05-07
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Threshold Pharmaceuticals
Phase 1 Completed
NCT01381822 2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1 Unknown
NCT00495144 2012-07-27
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
Threshold Pharmaceuticals
Phase 1 Completed